Your session is about to expire
← Back to Search
Nivolumab + Radiosurgery for Brain Cancer
Study Summary
This trial will test whether the combination of Nivolumab and SRS can help control cancer progression and improve patient survival.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have taken corticosteroids or other medications that weaken your immune system within the past 14 days.You have had fewer than 4 previous treatments for your condition.You have a current autoimmune disease, except for some specific cases.You have been diagnosed with certain types of lung cancer, melanoma, or kidney cancer.You should be in good enough health to carry out everyday activities and work, with little or no need for rest.You had a seizure within the last 7 days without taking corticosteroids.You are taking certain medications that can harm your liver.You have a type of cancer that is not non-small cell lung cancer (NSCLC) or clear cell renal cell carcinoma (ccRCC).You have a medical or mental health condition that could make taking Nivolumab dangerous.You have received certain medications or immunotherapy treatments in the past.You are currently taking certain types of immunotherapy medications.You have a history of chronic hepatitis B or C infection.You must be at least 18 years old.You cannot have an MRI scan.You have cancer that has spread to the brainstem.You have advanced cancer that has spread to the brain.You have brain metastasis that has not been treated with radiation before, and the total volume of the brain disease is no more than 10 cubic centimeters as shown in the MRI taken within 28 days before enrolling in the study.You have a brain disease that can be measured or evaluated.Your neurological function is good, with a score of 0-1 on a specific test, within the last 28 days.You can receive treatment with a specific type of radiosurgery system.
- Group 1: Radiosurgery and Nivolumab
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has a similar clinical trial ever been conducted before?
"Radiosurgery was first explored in 2012, when Ono Pharmaceutical Co. Ltd conducted their inaugural study of 659 patients. Subsequent Phase 1 & 2 trials were successful and Radiosurgery has since become a widely studied treatment method with 718 active investigations across 49 countries and 2354 cities."
What previous research has been conducted regarding Radiosurgery?
"At present, there are 82 Phase 3 trials and a total of 718 active studies for Radiosurgery. The vast majority of these experiments occur in Zürich, BE; however, it is possible to find research sites conducting this type of study across over 40 thousand global locations."
How many participants are partaking in this research investigation?
"This clinical trial has ended its recruitment period. Initially posted on June 2nd 2017, the study's last edit was on August 2nd 2022. For those looking for similar studies, there are currently 3697 trials searching for patients with carcinoma renal cell and 718 separate Radiosurgery investigations that remain open to participants."
Are patients able to enrol in this trial at present?
"This particular study is no longer enrolling participants. Its initial posting was on June 2nd 2017, with the latest update made on August 2nd 2022. For those who are still looking for other trials to join, there are currently 3697 clinical studies involving carcinoma and renal cell cases that are actively recruiting as well as 718 treatments related to radiosurgery in need of patients."
How detrimental is Radiosurgery to human wellbeing?
"Our team at Power assigned radiosurgery a score of 2 due to the presence of clinical data confirming its safety, despite the lack of evidence supporting efficacy."
How is Radiosurgery commonly being employed to alleviate health problems?
"Radio-surgery can be utilized to manage malignant neoplasms, unmanageable melanoma, and squamous cell carcinoma."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger